California
Biotech Insights

Biotech Leader Spotlight

Alan Cohen

CMO at Arcturus Therapeutics

June 11, 2026

Alan H. Cohen, MD is the Chief Medical Officer at Arcturus Therapeutics. He is a board-certified Pediatric Pulmonologist with a longstanding interest in cardio-respiratory illnesses. He has been clinically active for the balance of his 35+ years of practice, with a focus on caring for people with Cystic Fibrosis, as well as previously co-directing the largest and most active pediatric lung transplantation program in North America. In addition to his many years of clinical practice, biomedical and basic science research, and teaching, he has dedicated over 25 of his 35+ year-long professional career to drug discovery, in the Biotech & Pharma clinical/medical research space, at both small, entrepreneurial pre-IPO start-ups, as well as more well-established public companies worldwide. He has most recently worked in the fields of heart failure (amyloid-related) and pulmonary hypertension, respiratory infectious diseases (P. aeruginosa, influenza and RSV), as well as gene editing/gene therapy targeting monogenetically driven conditions, including rare and more common diseases such as alpha-1 antitrypsin deficiency, amyloidosis, cystic fibrosis, hemophilia and Fabry Disease.

Biotech Market Update

NewLimit raises $435M Series C, Nurix inks $2.3B deal with Roche, J&J acquires Firefly Bio

June 9, 2026

Recent Funding: NewLimit (SF) Raises $435M Series C to Take Age-Reprogramming Drug to Human Trials Longevity biotech NewLimit closed a $435M Series C led by Founders Fund with participation from Thrive Capital, Kleiner Perkins, Eli Lilly Ventures, and others, pushing its valuation to $3.1B — more than three times where it stood twelve months ago. […]

Biotech Market Update

Protuoso raises $9.5M Seed, Gilead cuts 51 roles, Vaccine Company acquired by Lilly

June 2, 2026

Recent Funding: Protuoso Biosciences (SF) Raises $9.5M Seed to Advance MUXBODY Biologics Platform The oversubscribed seed round — led by Taya Venture and Darwin Ventures with NSG Ventures, SEEDS, and others — will fund Protuoso’s modular MUXBODY fusion-protein platform, designed to engineer multi-specific biologics for cardiometabolic, oncology, and autoimmune indications. The company operates a therapeutic-agnostic […]

Biotech Leader Spotlight

Dolca Thomas

Co-founder & CEO of Neolaia Bio

May 28, 2026

Dr. Dolca Thomas is a physician scientist, transplant nephrologist/ immunologist with more than 20 years of experience in academia, large pharmaceutical companies, and biotech across multiple diverse therapeutic areas. She is the CEO of Neolaia Bio, venture partner/senior advisor at Samsara Biocapital and is currently an independent board director for UCB, and Ventus Therapeutics. She is also a scientific advisor for First Tracks (previously AnaptysBio). Prior to Neolaia, she was a board director for Chinook (acquired by Novartis 3.2 billion in 2023) and held multiple roles in biotech companies including Executive Vice President, Head of Research and Development and Chief Medical Officer at Equillium and the Chief Medical Officer of Principia Biopharma which was acquired by Sanofi September 2020 for 3.7 billion.

Biotech Market Update

cAMPfield launches with $180M, Edison Scientific and Genesis Molecular both partner with Incyte on AI drug development

May 26, 2026

Recent Funding: cAMPfield Therapeutics (SD) Launches with $180 Million Series A to Develop Licensed Inflammatory Disease Drugs cAMPfield Therapeutics has quietly secured $180 million in backing from a powerhouse group of investors including Novo Holdings, RA Capital, Frazier Life Sciences, and Venrock — following the increasingly popular model of building a company around drugs licensed […]

Biotech Market Update

Kyverna files FDA approval, BioAge Labs pivots to inflammation, Aardvark hits major setback

May 19, 2026

M&A, Deals, Partnerships: Quince Therapeutics (SF) Merges with Private Pulmonary Startup to Stay Alive on Nasdaq After its lead drug for a rare childhood neurological disease failed in a Phase 3 trial earlier this year, cash-strapped Quince Therapeutics is merging with private pulmonary startup Orphai Therapeutics in an all-stock deal that will keep the combined […]

California Biotech Insights

California
Biotech Insights